Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
From BIO-Europe, the biggest pharma and biotech partnering meeting in Europe, Scrip lists the five hottest topics of discussion and debate.
Lars Bruening, who recently succeeded Alexander Moscho as Bayer's CEO for the UK and Ireland, talks to Scrip about Brexit uncertainties and fostering the right dialog between pharma and healthcare systems.
Latest From Brexit
As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.
From ongoing progress in IO to revolutions in AI, and from pricing headaches to new therapies for migraine: Scrip has gleaned from experts and industry executives their expectations and predictions for 2018's hot topics. Here is our digest.
MSD's R&D head Roger Perlmutter and Sir John Bell tell Scrip the UK government needs to offer better manufacturing incentives to the life science sector and also encourage more efficient drug innovation there.
Nearly 18 months after the UK voted to leave the European Union, pharmaceutical companies and regulators are still in the dark as to what kind of regulatory arrangements will exist between the two parties after Brexit takes place in March 2019.
The UK pharmaceutical industry has welcomed the announcement that Brexit talks are to move on to trade deal discussions, but says a regulatory cooperation agreement and a fixed transition period are essential to safeguard European supply chains. Several pharma executives outlined some of their key concerns at a parliamentary committee hearing on Dec. 5.
Some of the loudest messages from UK government's Life Science Sector Deal was the importance of using real world evidence - and the uniqueness the British health ecosystem can offer to trail blazing innovation.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.